* Advanced Viral Research Corp., of Hallandale, Fla., said a double-blind trial assessing efficacy of Reticulose for AIDS is under way inBridgetown, Barbados. Laboratory studies showed the product, apeptide nucleic acid preparation, inhibited replication of HIV andstimulated the immune system to produce immunomodulators.
* Anergen Inc., of Redwood City, Calif., received a $2 millionlicense fee from N.V. Organon, of Oss, the Netherlands, for use ofAnergen's AnergiX technology for development of a peptide forrheumatoid arthritis. (See BioWorld Today, July 1, 1996, p. 1.)
* Innovir Laboratories Inc., of New York, said The Aries Fund andThe Aries Domestic Fund L.P. invested a total of $2 million inexchange for 4 million Innovir shares and 4 million Class C warrantsthat can be exercised for 50 cents each. The company also issued TheAries Fund an option to purchase 2 million shares and 2 million ClassC warrants, exercisable at 50 cents each, for $1 million.
* LeukoSite Inc., of Cambridge, Mass., received a Phase II SmallBusiness Innovation Research grant to develop a humanizedmonoclonal antibody to alpha-4 beta-7 and conduct preclincal testson the antibody. LeukoSite has shown an antibody to the lymphocytereceptor blocked lymphocyte infiltration and lessened symptoms in amodel of inflammatory bowel disease.
* MicroCarb Inc., of Gaithersburg, Md., changed its name to AntexBiologics. The company is listed on the OTC Bulletin Board underthe symbol ANTX.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo., said the FrenchMinistry of Health approved DaunoXome to treat advanced AIDS-related Kaposi's sarcoma in severely immunocompromised patients.The product now is approved in 15 countries.
(c) 1997 American Health Consultants. All rights reserved.